PMV Pharmaceuticals
PMVP
115 hedge funds and large institutions have $470M invested in PMV Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 35 increasing their positions, 39 reducing their positions, and 16 closing their positions.
159% more call options, than puts
Call options by funds: $1.88M | Put options by funds: $727K
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less funds holding
Funds holding: 120 → 115 (-5)
8.09% less ownership
Funds ownership: 127.52% → 119.42% (-8.1%)
10% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 39
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
24% less capital invested
Capital invested by funds: $614M → $470M (-$144M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$6.68M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$5.76M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.33M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.79M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$20.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.23M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.25M |
| 4 |
JP Morgan Chase
New York
|
-$6.5M |
| 5 |
State Street
Boston,
Massachusetts
|
-$6.29M |
PMVP Hedge Fund Activity: Q4 2022 in Review
115 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2022, worth a combined $470M — down 24% from $614M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PMVP and 13 opened new positions — a net loss of 3 holders — while 39 trimmed existing stakes and 35 added.
The largest buyer was Verition Fund Management, adding an estimated $6.68M. The largest seller was RA Capital Management, exiting entirely with an estimated $20.4M sold.
- 115 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2022, down from 120 in Q3 2022.
- Funds reported $470M of PMV Pharmaceuticals stock for Q4 2022, down 24% quarter-over-quarter.
- 13 funds opened new PMV Pharmaceuticals positions in Q4 2022 and 16 closed out, a net change of -3 holders.
- The largest PMV Pharmaceuticals buyer in Q4 2022 was Verition Fund Management, an estimated $6.68M added.
- The largest PMV Pharmaceuticals seller in Q4 2022 was RA Capital Management, an estimated $20.4M sold.
Based on aggregated 13F filings for Q4 2022.